Literature DB >> 3933028

Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia.

D P van Kammen, J P Docherty, S R Marder, J E Rosenblatt, W E Bunney.   

Abstract

d-Amphetamine (20 mg) was administered intravenously in a double-blind design to 17 schizophrenic patients with and without concurrent 3-week lithium carbonate pretreatment to evaluate the lithium attenuation of d-amphetamine effects which we had observed in affective disorder patients. Lithium significantly attenuated the acute d-amphetamine-induced changes in an activation-euphoria cluster and in the mannerisms and posturing item of the Brief Psychiatric Rating Scale. Because the psychosis-increasing effects of d-amphetamine were not significantly decreased, it is conceivable that the d-amphetamine-induced changes in activation and euphoria and in psychosis are regulated by different dopamine mechanisms. The small clinical effects seen at 3 weeks of lithium treatment in schizophrenic patients could be mediated by dopamine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933028     DOI: 10.1007/bf00431789

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  47 in total

1.  Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data.

Authors:  A R Cools; J M Van Rossum
Journal:  Psychopharmacologia       Date:  1976-02-02

2.  Regional alterations in rat brain neurotransmitter systems following chronic lithium treatment.

Authors:  A Maggi; S J Enna
Journal:  J Neurochem       Date:  1980-04       Impact factor: 5.372

3.  Antagonism of cocaine highs by lithium.

Authors:  A J Cronson; A Flemenbaum
Journal:  Am J Psychiatry       Date:  1978-07       Impact factor: 18.112

Review 4.  Two dopamine receptors: biochemistry, physiology and pharmacology.

Authors:  J C Stoof; J W Kebabian
Journal:  Life Sci       Date:  1984-12-03       Impact factor: 5.037

5.  Lithium and alpha-methyl-p-tyrosine prevent "manic" activity in rodents.

Authors:  C Davies; D J Sanger; H Steinberg; M Tomkiewicz; D C U'Prichard
Journal:  Psychopharmacologia       Date:  1974-04-23

6.  Simplified symptom registration in psychiatric trials: a statistical approach.

Authors:  V Hansen; A S Hagen; E H Lehmann; C Astrup
Journal:  Acta Psychiatr Scand       Date:  1974       Impact factor: 6.392

7.  Haloperidol and lithium blocking of the mood response to intravenous methylphenidate.

Authors:  D Wald; R P Ebstein; R H Belmaker
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

8.  Antipsychotic effects of lithium in schizophrenia.

Authors:  P E Alexander; D P van Kammen; W E Bunney
Journal:  Am J Psychiatry       Date:  1979-03       Impact factor: 18.112

9.  Extrapyramidal side effects with lithium treatment.

Authors:  J Kane; A Rifkin; F Quitkin; D F Klein
Journal:  Am J Psychiatry       Date:  1978-07       Impact factor: 18.112

10.  Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia.

Authors:  D P van Kammen; J P Docherty; S R Marder; J N Rayner; W E Bunney
Journal:  Arch Gen Psychiatry       Date:  1982-03
View more
  7 in total

1.  Acute lithium administration selectively lowers tyrosine levels in serum and brain.

Authors:  Hewlet G McFarlane; John Steele; Keenan Vinion; Rodolfo Bongiovanni; Manda Double; George E Jaskiw
Journal:  Brain Res       Date:  2011-08-27       Impact factor: 3.252

2.  Synergistic interaction between caloric restriction and amphetamine in food-unrelated approach behavior of rats.

Authors:  Kristine L Keller; Fiori R Vollrath-Smith; Mehrnoosh Jafari; Satoshi Ikemoto
Journal:  Psychopharmacology (Berl)       Date:  2013-10-08       Impact factor: 4.530

Review 3.  The behavioral actions of lithium in rodent models: leads to develop novel therapeutics.

Authors:  Kelley C O'Donnell; Todd D Gould
Journal:  Neurosci Biobehav Rev       Date:  2007-04-13       Impact factor: 8.989

Review 4.  Molecular actions and clinical pharmacogenetics of lithium therapy.

Authors:  Adem Can; Thomas G Schulze; Todd D Gould
Journal:  Pharmacol Biochem Behav       Date:  2014-02-15       Impact factor: 3.533

5.  Chronic lithium treatment rectifies maladaptive dopamine release in the nucleus accumbens.

Authors:  Adem Can; Douglas O Frost; Roger Cachope; Joseph F Cheer; Todd D Gould
Journal:  J Neurochem       Date:  2016-10-18       Impact factor: 5.372

6.  Antipsychotics for Amphetamine Psychosis. A Systematic Review.

Authors:  Dimy Fluyau; Paroma Mitra; Kervens Lorthe
Journal:  Front Psychiatry       Date:  2019-10-15       Impact factor: 4.157

Review 7.  Lithium for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John J McGrath
Journal:  Cochrane Database Syst Rev       Date:  2015-10-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.